MiNA Therapeutics, a London, UK-based maker of RNA activation therapeutics, completed a £23m ($30m) Series A equity financing.
The round was led by aMoon, with participation from existing investors. As part of the Series A financing, Dr. Gur Roshwalb, M.D., M.B.A., Managing Director at aMoon, has joined the Board of Directors at MiNA Therapeutics.
The proceeds from the financing will be used to advance the company’s pipeline of small activating RNA (“saRNA”) therapeutics, and to support the continued clinical development of MiNA’s lead candidate, MTL-CEBPA, as a combination treatment in cancer.
Led by Robert Habib, CEO, MiNA Therapeutics harnesses an innate mechanism of gene activation to enable the development of new medicines that restore normal function to patients’ cells.
MiNA’s lead candidate, MTL-CEBPA, is a first-in-class therapy that reduces immune suppression in the tumour microenvironment. MTL-CEBPA has been studied in clinical trials in more than 70 patients with advanced liver cancer, demonstrating good initial results. Used in combination with the standard primary cancer treatment drug, sorafenib, MTL-CEBPA improved the rate, duration and depth of response when compared to data independently reported from third-party studies with single agent sorafenib therapy. The additional funding will enable MiNA Therapeutics to conduct a Phase 2 study of MTL-CEBPA in combination with sorafenib in patients with advanced liver cancer and TIMEPOINT, an ongoing Phase I/Ib study of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignancies. Additionally, the proceeds will fund research activities to advance a pipeline of novel small activating RNA therapies for the treatment of cancer, metabolic and genetic diseases.
FinSMEs
10/09/2020